Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Already announced during last ER and projected to close in Q3. Reverse merger with Venus Concept. 15:1 RS. Proforma 19M shares o/s if recollection serves.
OCUL/EYPT - Only other bioerodible insert that I am aware of in preclinical experiments is Nicox/Re-Vana. Eyepoint/Nicox collaboration dropped last year. EYPT focused on commercialization of Dexycu and Yutig for cataract surgery and posterior segment uveitis respectively.
http://investors.eyepointpharma.com/static-files/848e2f30-aefd-4674-9d8e-f7d95ff8b9c4
ABEV - on the opposite side of the risk.
CVX - Divest out of north sea almost completely for 1.6B#. Still holds on to non-operated Claire.
covered today.
OXY/APC/TOT/BRK - A three ring circus is now a four ring circus.
https://www.bloomberg.com/news/articles/2019-05-30/icahn-challenges-occidental-s-hugely-overpriced-anadarko-deal?srnd=premium
PS - OXY now looking for buyers interested in APC's GOM assets as expected. The deep wounds from Piper Alpha never healed. They may have to keep Algeria - ouch.
Lots of questions rightfully about TSLA. I am not sure how to price "faith". There are a number of comparables available. Mobileye and GMcruise (recent raise) + a specialty auto making/sales component. I think of RACE as the latter analog. IMO the stock is cheap here. My 190 puts expired and I sold the 180s recently. Will add gradually to my small long position.
Ark has the bear case (EV auto component only) on their spreadsheet. Would be interested in what others provide in terms deltas wrt their bear case numbers. I view it as their best guess and I don't have an opinion on their guesses. I realise what I observe locally is not close to what is happening nationally. I was just at a place that is semi off grid and I only observed two residents at remote wooded location having solar panels (lots of them, 32 in customised metal fencing structure in one and roof panels in the other feeding very large homes). The area was overrun by late model Toyota Prius's and I only saw one Tesla 3 during my entire trip. The only wind turbines I saw was on the way back to SAN where SRE turbines were visible from sky high located at the boundary of the desert and a high plateau.
https://github.com/ARKInvest/ARK-Invest-Tesla-Valuation-Model/blob/master/Tesla%20Valuation%20for%20Github_5.27.19_v3.4.xlsx
People are assuming that setting up a core and fluid analysis lab is easy. It is not, has never been unless there are customers willing to accept bad data and I am not aware of any. The only partial alternative to clb is pts lab and they are private. Doesn't matter anyway. Look at the whole space. The market is sending a message. NOV joins the sick club. Still better than the offshore drillers that seem to be a few steps closer to the cliff.
https://investors.nov.com/static-files/3afbf0c8-acea-4e41-9623-f956bdf7e767
I am pretty sure that TOT was aware of the risk having dealt with Sonatrach for decades. There will be an expense that may be borne by Oxy in a form that doesn't impact the negotiated price on African assets. Algeria is not behaving differently than other international JV's where national oil companies have a stake in a sizable project(s).
O&G capital spending plans and stranded assets.
https://www.bloomberg.com/news/articles/2019-05-29/putting-a-price-on-the-risk-of-climate-change
ps catching up on stuff after a trip with limited grid access.
TRXC - Japanese Shonin clearance yesterday.
http://ir.transenterix.com/news-releases/news-release-details/transenterix-announces-japanese-regulatory-approval-senhance
CVX - dips toes into EV charging at stations. I am guessing that top CVX execs live in Alamo, Danville, San Ramon, Orinda and Lafayette, (Blackhawk is unincorporated so no data) and can experience for themselves the penetration of BEV's in their area ~3%.
https://www.bloomberg.com/news/articles/2019-05-20/oil-giant-chevron-offering-electric-car-charging-at-stations?srnd=hyperdrive
AMZN/KSS - brick and mortar experiment working out and expanding to all KSS stores. In house efforts and WFC buyout hasn't worked out yet. IMO it would be great if AMZN gets their online pharmacy going instead of just talking about it.
https://www.bloomberg.com/news/articles/2019-05-20/amazon-returns-why-kohl-s-is-expanding-program-to-all-its-stores
TSLA - btw the stock action could be all about uncertainty of China trade spat and how that impacts their Shanghai production and sales. Model 3 lack of demand has been circulating since fed tax credit reduction as short thesis.
TSLA - sold one otm put this morning on Wedbush analyst note that demand for model 3 is lacking. I could see demand for S and X stalling as potential buyers wait for the motor and range upgrade to 370 miles and faster charging rate. IMO pendulum has swung too far.
BEV/TSLA (battery EV) and engine types stats in CA as of Oct 2018. Trying to figure out a way to track the local market instead of anecdotal observations. I guessed anecdotally that TSLA has around 3% of our town's passenger car fleet and came surprising close. Actual number of all BEVs is 3.5%+. Yesterday as a numerical exercise, I counted the number of German luxury cars/suvs (Mercedes, BWM, Audi, Porsche) and Tesla's going in the opposite direction of me in traffic while going to my workout (round trip around 10 miles). I stopped at 100 German cars. At that point, I counted 14 Tesla's (majority being model 3, 3-X, 2-S). I estimate that German luxury cars make up around 20% of our town's. So 0.20*14/100 also gets me close to 3%. In my count of German cars, I included one BMW i3. As expected the wealthier places have higher BEV penetration. The highest I found was Los Altos, where a lot of SV execs live, at 6%. Amongst the biggest cities, SF leads as expected. LA and San Diego are still slightly under 1%. Central CA farming areas trail far behind the pack as expected. Tesla home turf of Fremont is close to 3.5% which 2X ahead of San Jose with the same demographics. File available in csv format as well on site.
https://www.dmv.ca.gov/portal/wcm/connect/1949a1b2-be57-4024-a921-5eb00babea68/MotorVehicleFuelTypes_City_102018.pdf?MOD=AJPERES&CVID=
Mozambique - The two samples that showed significant N2 looks like air contamination to me. Without those 2 samples, N2 average looks de minimis, like most other dry NG.
It's biogenic and trapped along with the NG. It probably come from the same organic source that generated the NG. So nature has granted Mozambique better biogenisis conditions and trapping size relative to NW shelf.
TOT/RDS/CVX - IMO one thing that almost everybody missed when looking the LNG projects is the CO2 composition in the produced stream. For the NW shelf projects it is ~20% and expensive to separate and reinject (permanent reservoir storage). Mozambique NG needs very little processing.
Oh that was a good one. Got my full supplement of vitamin H (humor) for the day. thx.
TOT - shares getting closer to where it was before announcement of purchase of APC Africa assets post Oxy takeover. I sold puts when the stock reacted in what I thought strange way. OXY meanwhile is testing the lows established back in early 2009. I was guessing that OXY ends up in the 40's unless oil prices come to the rescue first but didn't post that thought. Winner's curse.
HAIR - 10Q. Merger with Venus Concept on schedule for closing in Q3.
https://ir.restorationrobotics.com/node/7451/html
LUKOY - +4% presumably because of increased risk in the Persian gulf. Others up closer to 1-2%.
They skip the sham-TTF in trials. Excuses were the extra burden to both patients and caregivers. I don't know enough about the history of the device other than the original PMA was granted in 2011. There must have been data backing the efficacy of TTF. Insurance carriers will ask for sham data or trial given ASCO 2019 abstract.
https://www.ncbi.nlm.nih.gov/books/NBK513128/
NVCR - TTF == voodoo? Murky picture out of ASCO.
http://abstracts.asco.org/239/AbstView_239_263971.html
I need to stop the quiz after reviewing the 10ksb to jog my memory and found out I screwed up on the symbol. The proposed symbol by underwriter was "APOS" originally meant for Nasdaq listing. It was switched to AMEX listing and ended with the symbol APS. I wanted to short the IPO after a broker tried to sell me some. He said he would get fired if he tried to help me.
https://www.sec.gov/Archives/edgar/data/95047/000095013500004444/b36859sbe10ksb.txt
The year was 2000.
Memories of the dot com era and Henry Blodget referring to them as "POS"s. Here is a history quiz. What was the company that got the symbol POS for their IPO during dot com era and still got it off the ground? Not implying that either lyft or uber fits in the same bin, IMO they have real businesses but valuations are uncertain at this point in time.
NIO - have been short that one. May cover when they do their raise.
TRXC - CEO and CFO exercised options @ 1.39 and holds. Shares at levels just prior to original FDA 510K clearance. IMO the company has to raise capital given the sales not picking up till back half of this year.
i haven't paid attention to RIG either given the better economics of tight oil relative to deep water development. There are special cases like Guyana and satellite development close to infrastructure.
That was a tongue in cheek reference to the unknown companies with 3 letters in their logo getting popular. They probably have good steady fishing businesses as a big chunk of their revenues. Notice that klx list their fishing services in all product categories. LOL
There must be increased need for fishing services to go with that. Too bad there isn't any pure play fishing companies. KLXE is probably as close as you get to that.
Probably due to price fixing on generic atorvastatin.
"SLB business in Permian has been almost nonexistent for past 2 years"
Who is/are getting the logging and completion business?
EYPT - Q1 ER 2 days ago. Slow launch of Yutiq confirmed. Dexycu for cataract surgery patients started mid-March and still giving away samples. Latter will be a much bigger market than former.
https://finance.yahoo.com/news/eyepoint-pharmaceuticals-eypt-reports-q1-113011133.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147856977
So people want the P values for each pool wrt MACE that AZN release doesn't provide.
FGEN release does put bounds on P via confidence limits.
DD pool p >0.05
ID pool P < 0.05 (implied)
NDD pool p >0.05
AZN/FGEN - Details confuse people in other words. AZN release is detail light for those more comfortable with less details.
What's there to clarify?
https://www.astrazeneca.com/media-centre/press-releases/2019/pooled-analyses-of-the-roxadustat-global-phase-3-programme-confirmed-cardiovascular-safety.html
to summarize
NDD pool - roxadustat and placebo showed no clinically-meaningful difference
ID pool - patients on roxadustat do better than those who are on epoetin alfa
DD pool - roxadustat and epoetin alfa showed no clinically-meaningful difference